用于针对炎症性肠病的向治疗的口服酶响应纳米探针
Lin Cao1, Dengyi Duan1, Jing Peng1
1Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Journal of nanobiotechnology
|August 13, 2024
概括
我们开发了用于治疗和监测炎症性肠病 (IBD) 的新型纳米探针. 这些口服的纳米颗粒向结肠炎部位,为IBD管理提供了一种新的治疗术策略.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠病 (IBD) 是一种严重的胃肠道炎症状况.
- 目前的IBD治疗和监测方法在精度和非侵入性方面面临挑战.
研究的目的:
- 开发一种口服的,针对结肠炎的,用于IBD的听纳米探针.
- 为了使计算机断层扫描 (CT) 以成像为指导的治疗和IBD的监测.
主要方法:
- 开发了装有黄素 (Cur) 和氧化 (CeO2) 的核心外纳米探针 (Cur@PC-HA/CeO2 NPs).
- 氨酸 (HA) 修改使结肠炎的向和口服成为可能.
- CT成像用于监测小鼠中的纳米探针积累和治疗反应.
主要成果:
- 口服纳米探针通过HA向专门积累在大肠炎部位,提供CT增强24小时.
- 释放的Cur和CeO2具有抗炎和抗氧化作用,改善肠道微生物群和缓解症状.
- 结肠中CT衰减的减少与临床生物标志物相关,表明治疗反应和缓解.
结论:
- 这项研究提出了一种新的治疗术策略,将IBD治疗与实时响应监测相结合.
- 开发的纳米探针显示了先进IBD管理的潜力.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Ulcerative Colitis in IBD
131
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
131
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145


